Correction to: A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using Box-Benkhen design, in vitro and in vivo characterization

Heba F. Salem¹ · Shahira F. El-Menshaweh¹ · Rasha A. Khallaf¹ · Yasmine K. Rabea¹

Published online: 12 November 2019
© Controlled Release Society 2019

Correction to: Drug Delivery and Translational Research
<https://doi.org/10.1007/s13346-019-00676-5>

In the original article, there are errors in Tables 2 and 6.
Following are the corrected tables:

The online version of the original article can be found at <https://doi.org/10.1007/s13346-019-00676-5>

✉ Rasha A. Khallaf
rasha_khallaf@yahoo.com; Rasha.mahmoud@pharm.bsu.edu.eg

Heba F. Salem
Heba_salem@yahoo.co.uk

Shahira F. El-Menshaweh
Shaira.fawzy@gmail.com

Yasmine K. Rabea
yasmin.abdelaleem@pharm.bsu.edu.eg

¹ Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Shehata Hegazi Street, P.O. Box 62514, Beni Suef, Egypt

Table 2 Box-Behnken design responses of LER nanoethosomes formulation (means $\pm$ SD, $n = 3$)

Formulation code	Independent variables			Dependent variables (mean $\pm$ SD)				Polydispersity index (PDI)
	A	B	C	Y ₁	Y ₂	Y ₃	Y ₄	
1	1	0	− 1	92.98 $\pm$ 0.97	380.31 $\pm$ 5.9	40.8 $\pm$ 0.56	370.24 $\pm$ 23.00	0.232
2	− 1	0	− 1	60.31 $\pm$ 0.84	255.99 $\pm$ 5.67	56.81 $\pm$ 1.30	550.98 $\pm$ 11.03	0.281
3	− 1	0	1	55.87 $\pm$ 0.80	243.56 $\pm$ 2.97	57.32 $\pm$ 1.42	556.36 $\pm$ 13.57	0.309
4	− 1	− 1	0	49.26 $\pm$ 0.34	280.89 $\pm$ 1.25	45.22 $\pm$ 1.03	410.21 $\pm$ 10.21	0.339
5	0	0	0	85.98 $\pm$ 0.98	260.21 $\pm$ 2.32	55.22 $\pm$ 1.51	520.32 $\pm$ 9.62	0.237
6	1	0	1	89.01 $\pm$ 0.91	365.92 $\pm$ 4.31	41.3 $\pm$ 0.83	390.87 $\pm$ 12.65	0.270
7	− 1	1	1	65.45 $\pm$ 0.65	220.32 $\pm$ 4.72	59.51 $\pm$ 1.21	580.61 $\pm$ 5.68	0.160
8	1	1	0	97.22 $\pm$ 0.45	330.45 $\pm$ 5.01	46.22 $\pm$ 0.79	440.19 $\pm$ 14.54	0.257
9	1	− 1	0	87.22 $\pm$ 0.31	400.57 $\pm$ 5.52	35.21 $\pm$ 0.34	290.54 $\pm$ 10.99	0.389
10	0	1	− 1	93.28 $\pm$ 0.85	240.67 $\pm$ 5.00	57.66 $\pm$ 0.89	540.76 $\pm$ 13.84	0.324
11	0	1	1	89.38 $\pm$ 0.79	230.81 $\pm$ 2.0	56.88 $\pm$ 0.71	548.23 $\pm$ 15.00	0.260
12	− 1	1	0	70.98 $\pm$ 0.73	210.87 $\pm$ 3.0	60.29 $\pm$ 1.02	590.98 $\pm$ 6.87	0.145
13	0	0	0	87.88 $\pm$ 0.88	265.05 $\pm$ 2.32	54.88 $\pm$ 1.49	500.32 $\pm$ 12.85	0.262
14	0	− 1	− 1	80.32 $\pm$ 0.49	300.98 $\pm$ 4.58	41.22 $\pm$ 1.20	310.42 $\pm$ 7.29	0.318
15	0	− 1	1	75.3 $\pm$ 0.23	289.21 $\pm$ 3.21	42.77 $\pm$ 1.36	330.75 $\pm$ 9.62	0.370

Table 6 Pharmacokinetics parameters of LER-loaded nanoethosomal gel and oral LER suspension

Pharmacokinetics parameter	Oral LER suspension	Nanoethosomal LER gel
C _{max} (μg/ml) ^a	2.12 $\pm$ 0.24	6.02 $\pm$ 0.8
T _{max} (h) ^b	1	6
T _{1/2} (h)	5.23 $\pm$ 0.44	7.03 $\pm$ 0.48
k _e (h ^{−1})	0.132 $\pm$ 0.03	0.098 $\pm$ 0.001
MRT (h) ^c	6.11 $\pm$ 0.33	8.82 $\pm$ 0.25
AUC _(0–24) (μg.h/ml) ^d	13.64 $\pm$ 2.26	47.23 $\pm$ 7.08
AUC _(0–∞) (μg.h/ml)	14.62 $\pm$ 1.95	50.99 $\pm$ 7.13

^a Maximum serum concentration^b Time to reach C_{max}^c Mean residence time^d Area under the serum concentration-time curve